From: Prognostic value of miR-221 in human malignancy: evidence from 3041 subjects
Categories | Subgroups | No of studies | Pool HR | 95% CI | Result | I2 | P |
---|---|---|---|---|---|---|---|
All | OS | 22 | 1.93 | 1.43–2.60 | S | 80.4% | 0.000 |
Countries | Asian (Chinese) | 16 | 2.14 | 1.53–2.99 | S | 74.2% | 0.000 |
Non-Asian | 6 | 1.44 | 0.83–2.47 | NS | 83.3% | 0.000 | |
Samples origins | Tumor tissues | 13 | 1.61 | 1.13–2.29 | S | 81.4% | 0.000 |
Serum/blood | 7 | 3.25 | 2.15–4.92 | S | 42.2% | 0.109 | |
Marrow | 2 | 1.07 | 0.26–4.43 | NS | 85.4% | 0.009 | |
Sample sizes | > 100 | 7 | 2.28 | 1.29–4.11 | S | 85.9% | 0.000 |
≤100 | 15 | 1.80 | 1.25–2.59 | S | 78.4% | 0.000 | |
Cancer types | Colon cancer | 4 | 2.33 | 1.60–3.38 | S | 0.0% | 0.897 |
Liver cancer | 5 | 1.91 | 1.53–2.38 | S | 0.0% | 0.633 | |
Lung cancer | 2 | 2.02 | 1.45–2.81 | S | 0.0% | 0.486 | |
ALL | 2 | 1.07 | 0.26–4.43 | NS | 85.4% | 0.009 | |
Breast cancer | 2 | 2.02 | 0.22–18.81 | NS | 91.7% | 0.001 | |
Osteosarcoma | 2 | 2.24 | 0.23–22.29 | NS | 93.7% | 0.000 | |
Ovarian cancer | 2 | 0.94 | 0.17–5.17 | NS | 91.8% | 0.000 |